Table 4.
Final multivariable model identifying risk factors for melanoma after allogeneic HCT
| Characteristics* | Cases | Controls | OR | 95%CI | Overall P** |
|---|---|---|---|---|---|
| Ambient UVR | |||||
| Tertile 1 | 30 | 147 | ref | 0.10 | |
| Tertile 2 | 27 | 143 | 1.12 | (0.67, 1.87) | |
| Tertile 3 | 44 | 133 | 1.64 | (1.01, 2.67) | |
| Conditioning regimen | |||||
| MA: Busulfan ± others | 27 | 146 | ref | 0.26 | |
| MA: TBI ± others | 65 | 237 | 1.77 | (1.00, 3.15) | |
| MA: Other | 1 | 6 | 0.71 | (0.07, 6.91) | |
| RIC: TBI ± others | 10 | 49 | 1.75 | (0.69, 4.47) | |
| RIC: Busulfan ± others | 9 | 39 | 1.82 | (0.70, 4.76) | |
| RIC: Melphalan ± others | 14 | 36 | 2.60 | (1.13, 6.02) | |
| RIC: Fludarabine ± others | 10 | 26 | 2.72 | (1.02, 7.30) | |
| RIC: Other | 4 | 18 | 1.68 | (0.49, 5.76) | |
| Acute GVHD skin involvement† | |||||
| No acute GVHD | 45 | 224 | ref | 0.04 | |
| No/unknown skin involvement | 9 | 29 | 1.36 | (0.56, 3.32) | |
| Stage 0/1 | 25 | 120 | 1.14 | (0.64, 2.02) | |
| Stage 2+ | 61 | 184 | 1.92 | (1.19, 3.10) | |
| Chronic GVHD skin involvement | |||||
| No chronic GVHD | 48 | 202 | ref | 0.03 | |
| Missing skin involvement | 2 | 6 | 1.56 | (0.30, 8.20) | |
| No skin involvement | 24 | 57 | 1.91 | (1.03, 3.57) | |
| Yes skin involvement | 66 | 292 | 0.81 | (0.50, 1.29) | |
| Keratinocytic carcinoma | |||||
| No | 122 | 524 | ref | 0.02 | |
| Yes | 18 | 33 | 2.37 | (1.16, 4.83) |
Abbreviations: CI - confidence interval; GVHD - graft-versus-host disease; HCT - hematopoietic cell transplantation; MA - myeloablative; OR - odds ratio; ref - referent; RIC - reduced intensity conditioning; TBI - total body irradiation; UVR - ultraviolet radiation.
Patient, transplant, and post-transplant characteristics were included in the final multivariable model if P<0.05 for any specific category or the overall P<0.05.
The likelihood ratio statistic was calculated comparing the full model to a model without the variable of interest.
Acute GVHD skin involvement: stage 0/1 includes no rash or maculopapular rash <25% of body surface, stage 2+ includes maculopapular rash ≥25% of body surface or generalized erythroderma.